Diagnostic imaging devices in Alzheimer's disease

Expert Review of Medical Devices

Volumn 4, Issue 4, 2007, Pages 475-487

  Jelic, Vesna ^a   Wahlund, Lars Olof ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Diagnosis; Electroencephalography; Mild cognitive impairment; MRI; PET; Single positron emission CT

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; DOPAMINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N ACETYLASPARTIC ACID;

ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN SIZE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COPING BEHAVIOR; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; MEDICAL INSTRUMENTATION; METHODOLOGY; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; VALIDATION STUDY; VOLUMETRY;

ALZHEIMER DISEASE; BRAIN; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; PHENOTYPE; SENSITIVITY AND SPECIFICITY;

EID: 34447327504     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.4.4.475     Document Type: Review

References (95)

1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 17, 63-67 (2003).
2. Terry RD. Neuropathological changes in Alzheimer's disease. In: Progress in Brain Research (Volume 101). Svennerholm L, Asbury AK, Reisfeld RA et al. (Eds). Elsevier Science BV, Amsterdam, The Netherlands (1994).
3. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 9(Suppl.), 6-12 (1998).
4. Dickson DW, Crystal HA, Bevona C et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol, Aging 16, 285-304 (1995).
5. Berg L, McKeel DWJ, Miller JP et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55, 326-335 (1998).
6. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol. Histopathol. 10, 509-519 (1995).
7. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann. NY Acad. Sci. 924, 17-25 (2000).
8. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol. (Berl.) 82, 239-259 (1991).
9. Terry RD. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59(2), 1118-1119 (2000).
10. Jack CR, Petersen RC, Xu JC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403 (1999).
11. Bradley KM, O'Sullivan VT, Soper NDW et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125, 1772-1781 (2002).
12. Mosconi L, Perani D, Sorbi S et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63, 2332-2340 (2004).
13. Almkvist O. Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Acta Neurol. Scand. 165, 63-71 (1996).
14. Grober E, Dickson D, Sliwinski J et al. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 20, 573-579 (1999).
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM IV (4th Edition). American Psychiatric Association, Washington DC, USA (1994).
16. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308 (1999).
17. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194 (2004).
18. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256, 240-246 (2004).
19. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int. J. Psychogeriatr. 16, 129-140 (2004).
20. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1(2), 189-195 (2004).
21. Knottnerus JA, van Weel C, Muris JWM. Evaluation of diagnostic procedures. Br. Med. J. 324, 477-480 (2002).
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944 (1984).
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd Edition Revised) (DSM III-R). American Psychiatric Association, Washington DC, USA (1987).
24. WHO. The International Classification of Diseases (10th Edition, Revised) ICD-10. WHO, Geneva, Switzerland 311-388 (1992).
25. Galasko D, Hansen LA, Katzman R et al. Clinical - neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 51, 888-895 (1994).
26. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorect diagnosis of Alzheimer's disease. Arch. Neurol. 53, 35-42 (1996).
27. Knopmann DS, Dekosky ST, Cummings JL et al. Practice parameter. diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153 (2001).
28. Waldemar G, Dubois B, Enire M et al. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur. J. Neurol. 7, 133-144 (2000).
29. Jobbst KA, Smith AD, Szatmari M et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340, 1179-1183 (1992).
30. De Leon MJ, Golomb J, George AE et al. The radiologic prediction of Alzheimer's disease: the atrophic hippocampal formation. Am. J. Neuroradiol. 14, 897-906 (1993).
31. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: cointribution of structural neuroimaging. Neuroimage 18, 525-541 (2003).
32. Charmichael OT, Aizenstein HA, Davis SW et al. Atlas-based hippocampus segmentation in Alzheimer's disease and mild cognitive impairment. Neuroimage 27, 979-990 (2005).
33. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J. Magn. Reson. Imaging 16, 623-629(1997).
34. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 11, 805-821 (2000).
35. Coimbra A, Williams DS, Hostetler ED. The role of MRI and PET/SPECT in Alzheimer's disease. Curr. Top. Med. Chem. 6, 629-647 (2006).
36. Erkinjunti T, Lee DH, Gao F et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. Arch. Neurol. 50(3), 305-310 (1993).
37. Laakso MP, Soininen H, Partanen K et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of incorrectly classified subjects. Neurobiol. Aging 19, 23-31 (1998).
38. Laakso MP, Hallikainen M, Hanninen T et al. Diagnosis of Alzheimer's disease: MRI of the hippocampus vs delayed recall. Neuropsycholagia 38(5), 579-584 (2000).
39. Scheltens P, Fox N, Barkhof F et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 1, 13-21 (2002).
40. Gao FQ, Black SE, Leibovitch FS et al. Linear width of the medial temporal lobe can discriminate Alzheimer's disease from normal aging: the Sunnybrook Dementia study. Neurobiol. Aging 25(4), 441-448 (2004).
41. Xu Y, Jack CR Jr, O'Brien PC et al. Usefullness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54, 1760-1767 (2000).
42. Jack CR Jr, Petersen RC, Xu J et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 51, 993-999 (1998).
43. Wahlund L-O, Almkvist O, Blenow K et al. Evidence-based evaluations of magnetic resonance imaging as a diagnostic tool in dementia workup. Top. Magn. Reson. Imaging 16, 427-437 (2005).
44. Chan D, Fox NC, Scahill RI et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Neurology 57(10), 1756-1763 (2001).
45. Jack CR, Shiumg MM, Gunter JL et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62(4), 591-600 (2004).
46. Hanayu H, Shindo H, Kakizaki D, Abe K, Iwamoto T, Takasaki M. Increased water diffusion in cerebral white matter in Alzheimer's disease. Gerontology 43, 343-351 (1997).
47. Whitwell JL, Jack CR. Comparison between Alzheimer disease, frontotemporal lobar degeneration and normal aging with brain mapping. Top. Mag. Reson. Imaging 16, 409-425 (2005).
48. Scheltens P, Barkhof F, Leys D, Wolters EC, David R, Kamphorst W. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 45, 883-888 (1995).
49. Kantarci K, Jack CR Jr, Xu YC et al. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219, 101-107 (2001).
50. Kantarci K, Petersen RC, Boeve BF et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 64, 902-904 (2005).
51. Choi SH, Na DL, Chung CS, Lee KH, Na DG, Adair JC. Diffusion-weighted MRI in vascular dementia. Neurology 54, 83-89 (2000).
52. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99m Tv-HMPAO-SPECT in dementia. Am. J. Geriatr. Pychiatry 12(6), 554-569 (2004).
53. Hellman RS, Tikofsky RS, Van Heertum. R. et al. A multiinstitutional study of interobserver agreement in the evaluation of dementia with rCBF/SPET technetium-99m exametazime (HMPAO). Eur. J. Nucl. Med. 21, 306-313 (1994).
54. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J. Nucl. Med. 45, 594-607 (2004).
55. The Swedish Council on Technology Assessment in Health Care (SBU). Dementia - a systematic review. SBU, Stockholm, Sweden (2007) (In press).
56. Uchida Y, Minoshima S, Okada S, Kawata T, Ito H. Diagnosis of dementia using perfusion SPECT imaging at the. patient's initial visit to cognitive disorder clinic. Clin. Nucl. Med. 31, 764-773 (2006).
57. Costa DC, Walker Z, Walker RWH, Fontes FRG. Dementia with Lewy bodies versus Alzheimer's disease: role of dopamine transporter imaging. Mov. Disord. 18(Suppl. 7), S34-S38 (2003).
58. Marshall V. Grosset D. Role of domapine transporter imaging in routine clinical practice. Mov. Disord. 18 (12), 1415-1423 (2005).
59. Jacobs AH, Li H, Winkeler A et al. PET-based molecular imaging in neuroscience. Eur. J. Nucl. Med. Mol. Imaging 30, 1051-1065 (2003).
60. Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familiar Alzheimer's disease. JAMA 173, 942-947 (1995).
61. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85-94 (1997).
62. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316 (2002).
63. Imamura T, Ishii K, Sasaki M et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci. Lett. 235, 49-52 (1997).
64. Van der Borght T, Minoshima S, Giordani B et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J. Nucl. Med. 38, 797-802 (1997).
65. Ishii K, Sakamoto S, Sasaki M et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J. Nucl. Med. 39, 1977-1988 (1998).
66. Small GW. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J. Geriatr. Psychiatry Neurol. 19, 180-185 (2006).
67. Silverman DHS, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term clinical outcome. JAMA 286, 2120-2127 (2001).
68. Brooks W, Friedman S, Stidley C. Reproducibility of H-1 MRS in vivo. Magn. Reson. Med. 41, 193-197 (1999).
69. Valenzuela MJ, Sachdev P. Magnetic resonance spectrospcopy in AD. Neurology 56, 592-598 (2001).
70. Doraiswamy M, Charles C, Krishnan R. Prediction of cognitive decline in early Alzheimer's disease. Lancet 352, 1678-1678 (1998).
71. Jessen F, Block W, Traber F et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55, 684-688 (2000).
72. Miller BL, Moats R, Shonk T, Ernst T, Wooley S, Ross B. Alzheimer disease: depiction of increased cerebral: myoinositol with proton MR spectroscopy. Radiology 187, 433-437 (1993).
73. Lin A, Ross BD, Wong BD. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2, 197-214 (2005).
74. Jessen F, Traeber F, Feymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67(3), 528-530 (2006).
75. Robinson DJ, Merskey H, Blumet WT, Fry R, Williamson PC, Hachinski VC. Electroencephalography as an aid in the exclusion of Alzheimer's disease. Arch. Neurol. 51(3), 280-284 (1994).
76. Claus JJ, Kwa VIH, Teunisse S et al. Slowing on quantitative EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 167-174 (1998).
77. Jelic V. EEG in dementia, review of the past, view into the future. In: Depression and Dementia. Sarbadhikari SN (Ed.). Nova Science Publishers, Inc., NY, USA 245-304 (2005).
78. Pascual-Marqui RD, Lehman D, Koenig T et al. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naïve, first episode, productive schizophrenics. Psychiatr. Res. Neuroimaging 90(3), 169-179 (1999).
79. Dierks T, Jelic V, Pascual-Marqui RD et al. Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzhemier's disease. Clin. Neurophysiol. 11, 1817-1824 (2000).
80. Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationshiop between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann. Neurol. 32, 371-375 (1992).
81. Prvulovic D, Van de Ven V, Sack AT, Mauer K, Linden DEJ. Functional activation imaging in aping and dementia. Psychiat. Res. Neuroimaging 140, 97-113 (2005).
82. Anderson VC, Litvack ZN, Kaye JA. Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology. Top. Magn. Reson. Imaging 16, 438-452 (2005).
83. Rombouts SA, Barkof F, Veltman DJ et al. Functional MR imaging in Alzheimer's disease during memory encoding. Am J. Neuroradiol. 21, 1869-1875 (2000).
84. Machulda MM, Ward HA, Borowski B et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 61, 500-506 (2003).
85. Golby A, Silverberg G, Race E et al. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain 128, 773-787 (2005).
86. Johnson SC, Smitz TW, Moritz CH et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol. Aging 27, 1604-1612 (2006).
87. Dickerson BC, Salat DH, Greve DN et al. increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404-411 (2005).
88. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319 (2004).
89. Wang Y, Klunk WE, Debnath ML et al. Development of PET/SPECT agent for amyloid imaging in Alzheimer's disease. J. Mol. Sci. 24, 55-62 (2004).
90. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet 3, 519-527 (2004).
91. Nicols L, Pike VW, Cai L, Innis RB. Imaging and in vivo quantitation of β-amyloid: an exemplary biomarker for Alzheimer's disease? Biol. Psychiatry 59(10), 940-947 (2006).
92. Small GW, Kepe V, Ercoli LM et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652-2663 (2006).
93. Poduslo JF, Wengenack TM, Curran GL et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 11, 315-329 (2002).
94. Jack CR, Vengenack TM, Reyes DA et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 25(43), 10041-10048 (2005).
95. Beyer T, Townsend DT, Brun T et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 41(8), 1369-1379 (2000).